Press Releases

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Press Release: Execution of a share buyback agreement for up to €2 billion

Media Update: AAAAI: new data reinforce Sanofi’s leadership in immunology and scientific innovation for patients

Press Release: Sanofi announces buy back of shares from L’Oréal

Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Opella reaches study milestone for Cialis

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Press Release: Jean-Paul Kress to join Sanofi's Board of Directors

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Availability of the Q4 2024 Aide-mémoire

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US